Redmile Group, LLC - 16 May 2025 Form 3 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Reporting relationship: Director
Issuer ticker: ATRA
Reported as of: 16 May 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 23 May 2025, 16:01:24 UTC
Prior SEC filing: 02 Apr 2025
Next SEC filing: 30 May 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC

Key filing fact

Redmile Group, LLC filed Form 3 for Atara Biotherapeutics, Inc. (ATRA) on 23 May 2025.

Key facts

This page summarizes Redmile Group, LLC's Form 3 filing for Atara Biotherapeutics, Inc. (ATRA).
0 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 23 May 2025, 16:01.

Change

Previous filing in this sequence was filed on 02 Apr 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (2)

CIK 0001425738 Primary reporting owner

Redmile Group, LLC

Relationship: Director
Address: ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO
Signature: By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC
Signature date: 23 May 2025

CIK 0001650527

Green Jeremy

Relationship: Director
Address: C/O REDMILE GROUP, LLC (NY OFFICE), 45 W. 27TH STREET, FLOOR 11, NEW YORK
Signature: /s/ Jeremy Green
Signature date: 23 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATRA holding

Common Stock, par value $0.0001 per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 441,701
Date: 16 May 2025
Ownership: See Footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATRA holding Derivative

Pre-Funded Warrants to Purchase Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 16 May 2025
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 3,412,843
Exercise price
Footnotes: F1, F2

ATRA holding Derivative

Cash-settled Swaps

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 16 May 2025
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 4,103
Exercise price: $809.86
Footnotes: F2, F3, F4, F5, F6

ATRA holding Derivative

Cash-settled Swaps

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 16 May 2025
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 4,872
Exercise price: $9.32
Footnotes: F2, F3, F4, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The Warrants are exercisable at any time on or after the original issuance date until fully exercised, at an exercise price equal to $0.0001 per share, subject to a 9.99% beneficial ownership blocker. The Warrants have no expiration date.

Footnote F2

The reported securities are directly owned by certain private funds managed by Redmile Group, LLC (collectively, the "Funds") and may be deemed beneficially owned by Redmile Group, LLC ('Redmile") as investment manager of the Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F3

Certain Funds are parties to swap agreements with counterparties. Each notional share subject to each swap agreement represents the economic equivalent of one share of the Issuer's common stock. These agreements do not give the Reporting Persons direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparties thereto to acquire, hold, vote or dispose of any securities of the Issuer. Accordingly, the Reporting Persons disclaim any beneficial ownership in securities that may be referenced in such swap agreements or that may be held from time to time by any counterparties to the agreements.

Footnote F4

The Reporting Persons have the right to terminate and close out each swap at any time.

Footnote F5

Upon settlement of the various swap agreements, either (i) the counterparty will pay to the Reporting Persons in cash an amount determined in part by reference to any increase between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement or (ii) the Reporting Persons will pay to the counterparty in cash an amount determined in part by reference to any decrease between the reference price and the market value of the notional number of shares of Common Stock subject to the swap agreement.

Footnote F6

Represents the reference price associated with the swap agreements.

SEC remarks

Mr. Nachi Subramanian, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.